Benchmarking Deep Learning for PROTAC Ternary Complex Prediction
Proteins: Structure, Function, and Bioinformatics · 2026
DOI: 10.1002/prot.70117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proteins: Structure, Function, and Bioinformatics, 2026. Verfasst von Haoyu Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Ubiquitin-Protein Ligases, Deep Learning, Proteasome Endopeptidase Complex, Ubiquitin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Qingdao Science and Technology Demonstration Project.
Abstract (Originalsprache)
Proteolysis Targeting Chimeras (PROTACs) represent a transformative approach to drug development by leveraging the intracellular ubiquitin‐proteasome system (UPS) for the selective degradation of target proteins. A PROTAC molecule comprises three essential components: a ligand that binds to the E3 ubiquitin ligase, a ligand that targets the protein of interest, and a flexible linker that connects the two. This distinctive structure enables the PROTAC to simultaneously engage with both the target protein and the E3 ligase, facilitating their interaction. Such proximity initiates the ubiquitination of the target protein, marking it for recognition and subsequent degradation. In this study, we benchmark ternary complexes based on PROTACs using four recently employed predictive tools: Chai‐1, AlphaFold2, AlphaFold3, and Protenix. Comparative analysis indicated that the ternary complexes predicted by the four prediction tools demonstrated satisfactory accuracy (Cα‐RMSD < 10 Å). Among the evaluated tools, three—Chai‐1, AlphaFold3, and Protenix—demonstrated superior performance in over half of the tests, while AlphaFold2 exhibited comparatively lower performance. However, significant challenges remained in accurately predicting the orientation of POI and the E3 ligase (Cα‐RMSD < 10 Å when POI or E3 ligase were used as reference), as well as the position of the small molecule PROTAC (RMSD < 5 Å). By benchmarking these tools, we underscore recent advancements in protein structure prediction, enhance our understanding of the mechanisms underpinning PROTAC complexes, and provide a valuable reference for evaluating the binding conformations of other ternary complexes, as well as for the development of future predictive tools.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong, China.
- Marine Biomedical Research Institute of Qingdao, Qingdao, Shandong, China.
ORCID-Profile: Haoyu Chen, Fengjiao Wei, Jiajie Li, Zhuobin Shi, Shanshan Chen, Yu Fang, Shuxin Li, Xinru Gao, Lin Ju, Senbiao Fang, Ximing Xu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Qingdao Science and Technology Demonstration Project
Zitieren
APA
Chen, H., Wei, F., Li, J., Shi, Z., Chen, S., Fang, Y., Li, S., Gao, X., Ju, L., Fang, S., & Xu, X. (2026). Benchmarking Deep Learning for PROTAC Ternary Complex Prediction. Proteins: Structure, Function, and Bioinformatics. https://doi.org/10.1002/prot.70117
Vancouver
Chen H, Wei F, Li J, Shi Z, Chen S, Fang Y, et al. Benchmarking Deep Learning for PROTAC Ternary Complex Prediction. Proteins: Structure, Function, and Bioinformatics. 2026. doi:10.1002/prot.70117
BibTeX
@article{Chen2026,
author = {Chen, Haoyu and Wei, Fengjiao and Li, Jiajie and Shi, Zhuobin and Chen, Shanshan and Fang, Yu and Li, Shuxin and Gao, Xinru and Ju, Lin and Fang, Senbiao and Xu, Ximing},
title = {Benchmarking Deep Learning for PROTAC Ternary Complex Prediction},
journal = {Proteins: Structure, Function, and Bioinformatics},
year = {2026},
doi = {10.1002/prot.70117}
}
EUVIMED